Aligos Therapeutics, Inc.

ALGS Nasdaq SEC CIK 1799448
Follow Aligos Therapeutics Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Revenue, last quarter $2.8M +281.9% vs same quarter last year
Net income −$21.9M +30.7% vs same quarter last year
EPS, diluted −$2.09 +31.3% vs same quarter last year
Operating cash flow $1.5M +106% vs same quarter last year
Revenue by quarter
$606K
$311K
$965K
$741K
$169K
$2.8M
$0
$2.8M
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income8 fiscal years
  • Revenue
  • Net income
−$150M−$100M−$50M$0$50MFY18FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearRevenueNet income
FY25$2.2M−$24.2M
FY24$3.6M−$131.2M
FY23$6.2M−$87.7M
FY22$0−$96M
FY21$0−$128.3M
FY20$0−$108.5M
FY19-−$52.3M
FY18--
MarginsShare of revenue
  • Operating margin
  • Net margin
−6000%−4000%−2000%0%FY18FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearOperating marginNet margin
FY25−4024.9%−1106.7%
FY24−2469%−3633.6%
FY23−1423.5%−1416.2%
FY22--
FY21--
FY20--
FY19--
FY18--
Free cash flowOperating cash flow minus capital expenditure
−$150M−$100M−$50M$0FY18FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearFree cash flow
FY25-
FY24−$80.9M
FY23−$79M
FY22−$80.3M
FY21−$116.6M
FY20−$76.3M
FY19−$49.6M
FY18-
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • Aligos Therapeutics
  • Healthcare median
−4000%−3000%−2000%−1000%0%FY18FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearAligos TherapeuticsHealthcare median
FY25−1106.7%−30.6%
FY24−3633.6%−47%
FY23−1416.2%−58%
FY22-−80.4%
FY21-−71.9%
FY20-−62.2%
FY19-−46.3%
FY18-−49.6%